Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis

Bardhan, Karna Dev; Rensburg, C. Van

doi:10.1046/j.1365-2036.2001.01089.x

Cited by 31 publications

(20 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were no significant differences between the treatment groups with respect to GI symptom relief as assessed by the patient questionnaire. These findings are in good agreement with previous findings in patients with mild to severe GERD treated with 20 mg pantoprazole or 20 mg omeprazole MUPS [13]. The correlation between endoscopical healing and symptom relief was found to be rather low.…”

Section: Discussionsupporting

confidence: 92%

“…It is generally accepted that PPIs are significantly superior to H 2 -receptor antagonists [5, 6, 7, 8], prokinetics [9]and placebo [for review see 10, 11, 12]. Further, it was previously shown that pantoprazole and omeprazole are highly efficacious in the treatment of mild [13]and moderate to severe GERD [14, 15]. However, a direct comparison of equal doses of pantoprazole and omeprazole in patients with moderate to severe GERD has not been performed so far.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparable Efficacy of Pantoprazole and Omeprazole in Patients with Moderate to Severe Reflux Esophagitis

et al. 2003

View full text Add to dashboard Cite

Aim: To compare the efficacy and tolerability of pantoprazole 40 mg and omeprazole MUPS 40 mg in patients with moderate to severe gastroesophageal reflux disease (GERD). Methods: In this randomized, double-blind, parallel-group, multicenter study conducted in Austria, Germany, Portugal, Switzerland and The Netherlands, patients with endoscopically confirmed moderate to severe GERD (Savary/Miller esophagitis grade II/III) were enrolled. They received a once-daily dose of either 40 mg pantoprazole or 40 mg omeprazole MUPS. Healing was determined by endoscopy after 4 weeks of treatment. If patients were not healed, treatment was extended for another 4 weeks. An additional endoscopy was performed in these cases after 8 weeks of treatment. Healing was determined by endoscopy after 4 and 8 weeks. In addition, treatment effect on symptoms was evaluated by the investigator using a questionnaire assessing heartburn, reflux regurgitation and pain on swallowing at each visit, as well as by a self-administered questionnaire comprising further 24 gastrointestinal symptoms. Analyses were performed for the intention-to-treat (ITT) and the per-protocol (PP) population. In addition, patients with high compliance (HC: 90% ≤110%) were considered in a separate group. Adverse events and the influence of the Helicobacter pylori status were investigated. Results: A total of 669 outpatients were enrolled in the study, with 337 patients receiving pantoprazole and 332 omeprazole MUPS. The PP population consisted of 552 patients, 282 treated with pantoprazole and 270 with omeprazole MUPS. The healing rates in both treatment groups were shown to be equivalent and were higher in patients who adhered closely to the administration protocol (HC). According to ITT (ITT_HC) analyses, healing rates were 65.3% (77.4%) in the pantoprazole and 66.3% (74.7%) in the omeprazole group after 4 weeks. Furthermore, patients infected with H. pylori had slightly but not significantly higher healing rates than those with a negative test result. The safety profile of both treatments was comparable. Conclusion: Pantoprazole 40 mg and omeprazole MUPS 40 mg were equivalent with respect to healing after 4 and 8 weeks of treatment in patients with reflux esophagitis grade II/III. Overall, HC patients had higher healing rates than the regular compliant patients. Both drugs were well tolerated and safe.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Comparable Efficacy of Pantoprazole and Omeprazole in Patients with Moderate to Severe Reflux Esophagitis

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Better 24-hour pH control was accomplished in patients treated with omeprazole and the addition of a bedtime H 2 RA to control nighttime acid [82]. In addition, Bardhan and van Rensburg [83]compared the symptom relief and healing efficacies of omeprazole 20 mg with that of pantoprazole 20 mg in 328 patients with grade I esophagitis. After 4 and 8 weeks of therapy, both drugs achieved comparatively high symptom relief and healing rates in these patients, supporting the lack of clinically significant difference between these two doses.…”

Section: Gastroesophageal Reflux Diseasementioning

confidence: 99%

The Clinical Importance of Proton Pump Inhibitor Pharmacokinetics

Yacyshyn

Thomson

2002

Digestion

View full text Add to dashboard Cite

Achieving the optimal clinical response for patients with upper gastrointestinal peptic disease is important. This response depends on the pathology treated as well as on the choice of proton pump inhibitor. Here, we identify factors in specific disease therapy and proton pump inhibitor (PPI) pharmacokinetic and pharmacodynamic characteristics that help us achieve this goal. These include differences in PPI bioavailability and acid-suppressive effects. Available data indicate that PPIs appear to have similar potency on a milligram basis, and that omeprazole and lansoprazole are more frequently double dosed than pantoprazole. The lower propensity for double dosing with pantoprazole may also result in lower medication acquisition costs and a reduction in physician visits due to ineffective therapy with the standard dosing of these other agents.

show abstract

“…Dauerhafte Symptombefreiung Auch eine dauerhafte Symptombefreiung (ReQuest TM -GI) wurde unter Pantoprazol etwa zwei Tage eher erreicht (22,7 Tage) als unter Omeprazol (24,6 Tage) (n. s.). Die Ergebnisse in der PP-Population waren hierzu vergleichbar.…”

Section: Sekundäre Zielkriterienunclassified

Wachsender Kostendruck im Gesundheitswesen kann zu einer Beeinträchtigung der Behandlungsqualität bei Refluxpatienten führen

Gillessen¹,

Schöffel²,

Naumburger³

2006

Z Gastroenterol

View full text Add to dashboard Cite

show abstract

Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis

Cited by 31 publications

References 12 publications

Comparable Efficacy of Pantoprazole and Omeprazole in Patients with Moderate to Severe Reflux Esophagitis

Comparable Efficacy of Pantoprazole and Omeprazole in Patients with Moderate to Severe Reflux Esophagitis

The Clinical Importance of Proton Pump Inhibitor Pharmacokinetics

Wachsender Kostendruck im Gesundheitswesen kann zu einer Beeinträchtigung der Behandlungsqualität bei Refluxpatienten führen

Contact Info

Product

Resources

About